Vanda Pharmaceuticals Stock In The News
VNDA Stock | USD 4.95 0.29 5.53% |
The tone or emotional content of news articles related to Vanda Pharmaceuticals can affect its prices. Positive news sentiment can lead to an increase in demand for Vanda Pharmaceuticals' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Vanda Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Vanda Pharmaceuticals. The specific impact of Vanda Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Vanda Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Vanda Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Vanda Pharmaceuticals Backtesting and Vanda Pharmaceuticals Hype Analysis. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.
Vanda |
Vanda Pharmaceuticals Today Top News and Investor Outlook
Vanda Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Vanda and other traded companies coverage. We help investors stay connected with Vanda headlines for the 18th of April 2024 to make an informed investment decision based on correlating the impacts of news items on Vanda Stock performance. Please note that trading solely based on the Vanda Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.Vanda Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Vanda earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Vanda Pharmaceuticals that are available to investors today. That information is available publicly through Vanda media outlets and privately through word of mouth or via Vanda internal channels. However, regardless of the origin, that massive amount of Vanda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vanda Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vanda Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vanda Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vanda Pharmaceuticals alpha.
Vanda Largest EPS Surprises
Earnings surprises can significantly impact Vanda Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-10-28 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2017-05-02 | 2017-03-31 | -0.19 | -0.17 | 0.02 | 10 | ||
2015-11-03 | 2015-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2022-11-02 | 2022-09-30 | 0.09 | 0.06 | -0.03 | 33 | ||
2022-02-23 | 2021-12-31 | 0.09 | 0.12 | 0.03 | 33 | ||
2021-07-28 | 2021-06-30 | 0.14 | 0.17 | 0.03 | 21 |
Vanda Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Vanda Pharmaceuticals Stock. Current markets are slightly bullish. About 56% of major world exchanges and indexes are currently up. See today's market update for more information.17th of April 2024
Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Paks Takeover Bid Valued Up ... at benzinga.com
15th of April 2024
Vanda Pharmaceuticals Declines More Than Market Some Information for Investors at zacks.com
12th of April 2024
Vanda Pharmaceuticals sheds US37m, company earnings and investor returns have been trendin... at simplywall.st
8th of April 2024
AstraZenecas Enhertu Gets FDA Nod for Solid Tumors at finance.yahoo.com
4th of April 2024
Biotech Stock Roundup IRON, VERV Down on Study Updates, BMYs Drug News More at benzinga.com
3rd of April 2024
EDR Stock Alert Endeavor Group Is Going Private for 13 Billion at investorplace.com
2nd of April 2024
US FDA approves Vandas drug for bipolar disorder at finance.yahoo.com
8th of March 2024
Q2 2019 Vanda Pharmaceuticals Inc Earnings Call Transcript at gurufocus.com
29th of February 2024
Amicus Q4 Earnings Beat, Revenues Meet Estimates at finance.yahoo.com
21st of February 2024
Acquisition by Joakim Wijkstrom of 32700 shares of Vanda Pharmaceuticals subject to Rule 1... at Joakim Wijkstrom
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vanda Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vanda Pharmaceuticals' short interest history, or implied volatility extrapolated from Vanda Pharmaceuticals options trading.
Check out Vanda Pharmaceuticals Backtesting and Vanda Pharmaceuticals Hype Analysis. For information on how to trade Vanda Stock refer to our How to Trade Vanda Stock guide.Note that the Vanda Pharmaceuticals information on this page should be used as a complementary analysis to other Vanda Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Vanda Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vanda Pharmaceuticals. If investors know Vanda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vanda Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.04 | Revenue Per Share 3.357 | Quarterly Revenue Growth (0.30) | Return On Assets (0.01) |
The market value of Vanda Pharmaceuticals is measured differently than its book value, which is the value of Vanda that is recorded on the company's balance sheet. Investors also form their own opinion of Vanda Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vanda Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vanda Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vanda Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vanda Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vanda Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vanda Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.